Biomedical Engineering Conference | AICBES2025 | Biomedical Systems | Amsterdam | Top Conferences in Biomedical Engineering

Dr. Xijin Hua

University of Exeter, UK

Title: Innovations in Biomedical Practice: the Integration of Musculoskeletal Modelling and 3D Printed Devices

Dr. Xijin Hua is currently a Lecturer / Assistant Professor in the Department of Engineering at the University of Exeter, UK. Prior to joining the University of Exeter, he obtained his PhD degree from the Institute of Medical and Biological Engineering, School of Mechanical Engineering at the University of Leeds, UK. Subsequently, he served as a European Marie-Curie Individual Fellow, first at ETH Zurich in Switzerland and later at the University of Cambridge in the UK. Dr Hua’s research interests encompass musculoskeletal and tissue biomechanics, human movement analysis, metamaterials, additive manufacturing, and medical devices, including human joint replacements, orthoses, and exoskeletons. Specifically, his research focuses on developing advanced computational modelling and simulation, and integrating these simulations with human movement analysis to investigate the biomechanics of the musculoskeletal system, soft tissue, muscle function and dysfunction, and joint loading. By leveraging 3D printing technology, his research also supports the development of metamaterials by exploring their mechanics and properties, and their applications on the design, development, and manufacturing of medical devices for the prevention and rehabilitation of neuromusculoskeletal disorders, including Parkinson's diseases, cerebral palsy, and joint osteoarthritis. Dr. Hua has published 2 book chapters, over 25 high-impact journal papers, and 20 conference proceedings. He has also been regular reviewer of top scientific journals such as Journal of Biomechanics, Computer Methods and Programs in Biomedicine, Scientific Reports, etc.

Dr. Roderick Slavcev

University of Waterloo School of Pharmacy, Canada

Title: The intelligent Phage-Assembled Gene Expression (iPhAGE) system: a platform for the development of non-invasive, redosable, and targeted gene therapy

Roderick Slavcev is an associate professor with the University of Waterloo’s School of Pharmacy. Dr. Slavcev’s research specializes in bacteriophage-based biotechnology and exploits phage genetic systems and phage themselves in the generation of novel therapeutic platforms. With a particular focus on coliphages, his lab’s research designs and constructs vectors for novel vaccines, gene delivery systems, and immunotherapeutics. In addition, his team identifies and applies novel phage genomic anti-bacterial genes with potential phage therapy applications. Research in the Theraphage lab is heavily multidisciplinary, integrating genetics, molecular biology, microbiology, gene therapy, virology, therapeutic design, and synthetic in vivo biology. Roderick comes to the University of Waterloo with a MBA specialized in biotechnology management and commercialization. As the Professor of Business and Entrepreneurship, Roderick currently directs and delivers the School of Pharmacy's award-winning business curriculum initiative. He was also instrumental in the designing and development of the first Medical Microbiology Laboratory to be offered by a Canadian Pharmacy curriculum and leads the development of a Continuing Education initiative to bring Strategic Management and Leadership to practicing pharmacists. Dr. Slavcev is also the Chief Technology Officer of Mediphage Bioceuticals in Toronto, as well as a Principle Investigator at the Centre for Eye and Vision Research (CEVR) in Hong Kong.

Pablo Botella Asunción

Title: Will be update soon

Pablo Botella Asunción graduated in Pharmacy from the University of Valencia in 1988, received his PhD from the same university in 1993, and was awarded with honors in 1994. As a post-doctoral researcher, he worked under the supervision of Prof. Avelino Corma Canos and Prof. Jose Manuel Lopez Nieto at the Instituto de Tecnologia Quimica (Universitat Politècnica de València-Spanish National Research Council, UPV-CSIC). In 2003 he was selected as a Ramon y Cajal researcher at the ITQ and in 2007 he was granted the I3 Researcher Award. On that same year he was appointed as a CSIC Tenured Scientist at the Instituto de Tecnologia Quimica. Under the support of Salvador de Madariaga Program, he stayed as Visiting Researcher at the University of Vermont (VT, USA) in 2013, working with Prof. Landry. His current research is devoted to Nanomedicine, addressing medical nanoscale-structured material and devices for targeted delivery and controlled release of drugs and other biologically active agents. Special interest is dedicated to the development of organic-inorganic nanohybrid-based stimuli-responsive systems, as well as stable magnetic nanoparticles for diagnostic imaging. Also important in his research is the study of the immune reaction and protein corona formation produced after nanoparticle systemic administration, as well as its application to detect and amplify novel biomarkers of specific pathologies. He has written more than 80 publications with a h-index=39 (Scopus) and is co-inventor of 14 patents, three of them related to an environmentally benign industrial process, currently in use by Huntsman Polyurethanes LCC company. Another two patents claim a novel anti-inflammatory agent for therapy of pathologies associated to a cytokine storm, which is currently waiting approval for clinical trials in Phase I and II. He is a member of the Editorial Board of Nanomaterials journal (MDPI) since 2020.

Keynote Speakers